Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07477639 · ClinicalTrials.gov registry record · Phase 1

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

A Phase 1 study of Multiple Sclerosis and Multiple Sclerosis (MS) Primary Progressive, sponsored by Tr1X.

Recruiting
Registry status
Phase 1
Development phase
39
Enrollment target
2
Study locations

NCT07477639 is a Phase 1 study of Multiple Sclerosis and Multiple Sclerosis (MS) Primary Progressive that is actively recruiting participants, run by Tr1X. The registered enrollment target is 39 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07477639, a Phase 1 study of Multiple Sclerosis and Multiple Sclerosis (MS) Primary Progressive, is actively recruiting participants, sponsored by Tr1X.

RECRUITING
Registry status
Phase 1
Development phase
39 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS? * At what dose does TRX319 work the best to treat participants with primary and or secondary progressive MS? * Is pre-conditioning (with Bendamustine) needed to allow TRX319 to better treat participants with primary and/or secondary progressive MS? Participants will be asked to be on study for up 1 year and may receive up to 3 total administrations of TRX319. While on study, participants will have blood tests and other assessments (MRI scans and lumbar punctures) done to understand the safety of TRX319 and how it may benefit their multiple sclerosis.

Conditions Studied

Multiple Sclerosis Multiple Sclerosis (MS) Primary Progressive Primary Progressive Multiple Sclerosis Multiple Sclerosis (MS) Secondary Progressive Secondary Progressive Multiple Sclerosis (SPMS)

Interventions

  • DRUG Bendamustine
  • BIOLOGICAL TRX319

Study Locations (2)

Kansas

  • University of Kansas Medical Center - Kansas City

Missouri

  • Washington University, St. Louis - St Louis

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2026-03
Est. Completion 2029-01
Phase Phase 1

Sponsor

Tr1X

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07477639

The ClinicalTrials.gov registry entry for NCT07477639 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower). The listed sponsor is Tr1X, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Bendamustine is the first listed.

NCT07477639 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Missouri.

Frequently Asked Questions

What is clinical trial NCT07477639 about?

NCT07477639 is a clinical study titled "Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis". The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive ...

What is the current status of trial NCT07477639?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2026-03. Estimated completion is 2029-01.

What conditions does trial NCT07477639 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Primary Progressive Multiple Sclerosis, Multiple Sclerosis (MS) Secondary Progressive, Secondary Progressive Multiple Sclerosis (SPMS).

What interventions are being tested in trial NCT07477639?

The interventions under investigation include: Bendamustine (DRUG), TRX319 (BIOLOGICAL).

Who is sponsoring clinical trial NCT07477639?

This trial is sponsored by Tr1X, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07477639 being conducted?

This trial has 2 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

Multiple Sclerosis (MS) Primary Progressive

All registered trials for this condition

Kansas

All trials with a study site in Kansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.